MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Author: Tang Q, Tu YQ, Chen JH, Lyu XJ, Yan DD.
Journal: Zhonghua Zhong Liu Za Zhi; 2018 Jun 23; 40(6):462-466. PubMed ID: 29936774.
Abstract:
Objective: To compare the curative effect of postoperative concurrent chemoradiotherapy (CCRT) and radiation therapy (RT) alone on early-stage cervical cancer patients with intermediate-risk factors. Methods: Clinical data of patients with early stage (ⅠB-ⅡA) cervical cancer who underwent radical hysterectomy and pelvic lymphadenectomy in Zhejiang Cancer Hospital between January 2008 and December 2011 were retrospectively analyzed. Cervical squamous cell carcinoma patients with more than two intermediate-risk factors, including lymphatic vascular infiltration, depth of cervical stromal infiltration >1/2 cm or tumor size >4 cm, were screened. Among them, 80 patients were divided into the RT group, 137 patients were divided into the CCRT group. The survivals of these patients were analyzed. Results: At the end of the follow-up period, a total of 22 patients were dead, one patient was alive with neoplasm. There were 23 patients who occurred recurrence/ metastasis, 14 of them were in the RT group and 9 were in the CCRT group. The 5-year progression free survival (PFS) and 5-year overall survival (OS) rate of the entire cohort were 89.9% and 89.8%, respectively. The 5-year PFS rate of RT group was 82.4%, the 5-year PFS rate of CCRT group was 94.1%, and the difference between the two groups was statistically significant (P=0.013). The 5-year OS rate of RT group was 85.1%, the 5-year OS rate of CCRT group was 92.7%, and the difference between the two groups was statistically significant (P=0.049). Univariate analysis showed that therapeutic modality was associated with the 5-year DFS and OS of early-stage cervical cancer patients with intermediate-risk factors (P<0.05). The results of multivariate analysis showed that therapeutic modality was an independent prognostic factor of favorable PFS (RR=3.741, 95% CI: 1.506-9.289, P=0.004) and OS (RR=2.754, 95%CI=1.143-6.637, P=0.024). Neither of the two groups occurred severe anemia. However, the incidence of mild and moderate anemia in the CCRT group was higher than that of RT group (P<0.001). The incidence of leukocytopenia severer than grade Ⅲ in the CCRT group was significantly higher than that of RT group (P<0.001). However, the patients could recover quickly with the treatment of granulocyte colony-stimulating factor. Conclusion: Postoperative CCRT improves the survival of early stage cervical cancer patients with two or more intermediate-risk factors. 目的： 探讨同步放化疗对早期宫颈癌术后中危患者的疗效。 方法： 回顾性分析2008年1月至2011年12月浙江省肿瘤医院收治的行广泛性子宫切除术＋盆腔淋巴结清扫术的早期(ⅠB～ⅡA期)宫颈癌患者的临床资料，从中筛选出术后病理为鳞状细胞癌，伴有以下2～3个中危因素(淋巴脉管浸润、肿瘤浸润深度>1/2或肿瘤大小>4 cm)的患者。其中单纯放疗组80例，同步放化疗组137例，分析患者的生存情况。 结果： 全组死亡22例，带瘤生存1例，复发转移23例，其中单纯放疗组复发转移14例，同步放化疗组复发转移9例。全组患者的5年无进展生存率和5年总生存率分别为89.9%和89.8%。单纯放疗组患者的5年无进展生存率为82.4%，同步放化疗组患者的5年无进展生存率为94.1%，差异有统计学意义(P＝0.013)。单纯放疗组患者的5年生存率为85.1%，同步放化疗组患者的5年生存率为92.7%，差异有统计学意义(P＝0.049)。单因素分析结果显示，治疗方式与早期宫颈癌术后中危患者的5年无进展生存率和5年总生存率均有关(均P<0.05)。多因素分析结果显示，治疗方式是影响早期宫颈癌术后中危患者无进展生存(RR＝3.741，95%CI为1.506～9.289，P＝0.004)和总生存(RR＝2.754，95%CI为1.143～6.637，P＝0.024)的独立因素。两组患者均无重度及以上贫血发生，但同步放化疗组患者轻中度贫血的发生率高于单纯放疗组(P<0.001)，同步放化疗组3级及以上白细胞下降的发生率也明显高于单纯放疗组(P<0.001)，但患者经过粒细胞集落刺激因子等积极治疗可迅速恢复。 结论： 同步放化疗能够改善早期宫颈癌术后伴有2～3个中危因素者的预后，且急性骨髓抑制可耐受。.

[Abstract] [Full Text] [Related] [New Search]